



Australian Government
Department of Health
Therapeutic Goods Administration

Personalised Medical Devices Framework

Regulatory changes to custom-made
medical devices



Rebecca Bateson
Assistant Director, Devices Emerging Technology and Diagnostics,
Therapeutic Goods Administration

9 FEBRUARY, 2021

TGA Health Safety
Regulation

Welcome

- This webinar is being recorded
- Slides will be made available on the TGA website
- To ask a question to the **speaker** – Please use the **Q&A** tool
 - Messages will only be visible to the moderator and speaker
 - Questions will be answered at the end of the presentation
- If you need to contact the moderator – please use the **‘Chat’** function
- Relevant links will be sent to you via the chat function box
- Live polls will be conducted throughout this event.



Difficulties hearing from computer?

Check your settings located under “**Audio & Video**” tab located top of your screen:

OR

Dial: +61-2-9338-2221 **Passcode:** 165 941 5817


Overview

- Custom-made medical devices exempt under the *Therapeutic Goods (Medical Devices) Regulations 2002*
- Traditionally these devices were low risk
- Rapid advances in technology mean they can now be high risk
- Public consultation and collaboration through the International Medical Device Regulator's Forum
- A new regulatory framework for personalised medical devices commencing on **25 February 2021**




Overview of the changes

25 February 2021 –
regulatory amendments
commence




Custom-made medical devices

- Continue to be exempt from inclusion in the ARTG
- Excludes
 - Patient-matched devices (new definition)
 - Adaptable medical devices (new definition for an existing concept)
- New obligations
 - Information to be supplied with the device
 - Record keeping requirements
 - § a minimum of **5 years** after the date of manufacture if the device is **non-implantable**; or
 - § a minimum of **15 years** after the date of manufacture if the device is **implantable**.
 - Annual reporting
 - Inspection and review



25 February 2021 – new regulatory requirements commence

01 October 2021 – first annual report due



Patient-matched medical devices


- Manufactured within a “design envelope”
- Production processes can be validated, verified or reproduced
- No longer exempt – must be included in the ARTG
- Notify the TGA by **25 August 2021** to access transition arrangements
- Submit an application for inclusion **before 1 November 2024**



25 February 2021 – new definition commences


25 August 2021 – notification period for transitional devices ends

01 November 2024 – transition period ends



Medical Device Production System

- A validated, multi-component design and production system that a manufacturer can supply to health professionals and healthcare facilities, to produce a specific type of personalised medical device in-house.



MDPS continued

- COMING SOON – definition commences 25 February but there's more work to be done before MDPSs can be included in the ARTG.
- Health professionals (or a suitably qualified person within a healthcare facility) who use an MDPS to produce a medical device will not need to meet the regulatory obligations of a manufacturer.
- The MDPS must:
 - be included in the ARTG;
 - classified at the same level as the device it produces; and
 - be supplied with comprehensive instructions to allow the healthcare professional (or qualified person) to safely produce a device commensurate with the intended purpose of the MDPS.



Adaptable medical device

- A new definition for an existing concept
- Mass-produced and designed to be modified at the point of care to suit a particular patient.
- Definition introduced to provide clarity
- Adaptable medical devices **continue** to require inclusion in the ARTG before they can be supplied.
- Essential principle 13.4(3) will specifically require adaptable medical devices are supplied with instructions to allow safe modification/assembly at the point of care.



Diagnostic images and anatomical models

From 25 February 2021, the following will be classed as Class IIa:

- devices used to record patient images for diagnosis or monitoring of a disease, injury or disability or the investigation of a physiological process, where the images are acquired through a method that relies on energy outside the visible spectrum (ultrasounds and magnetic resonance imaging(MRI), for example);
- anatomical models (physical or virtual) for the diagnosis and/or monitoring of a disease, injury or disability or the investigation of a physiological process; and
- software-based devices that are used to generate a virtual anatomical model for the diagnosis and/or monitoring of a disease, injury or disability or the investigation of a physiological process.



Important dates – what to do

- Read the guidance
- Take the stakeholder survey
- Register for transition by **25 August 2021**
 - Custom-made to patient-matched
 - Reclassification
- For custom-made devices – submit your first annual report by **1 October 2021**
- Submit your application for inclusion/reclassification by **1 November 2024**



Finding help - SME Assist

- **Targets** the needs of small to medium enterprises (SMEs), start-ups, researchers and those unfamiliar with therapeutic goods regulation
- **Assists** users with navigating the ‘regulatory maze’
- The service offers:
 - guidance articles
 - interactive decision tools
 - educational face-to-face workshops across Australia
 - recorded presentations on regulatory obligations
 - email and phone support
 - a subscription service to keep up-to-date with news and events

The TGA website (and SME Assist hub) contains useful information about the regulation of therapeutic goods and contact details for different areas of TGA



🔗 tga.gov.au/sme-assist
* sme.assist@tga.gov.au
(1800 020 653

More information



TGA website www.tga.gov.au



TGA Facebook <https://www.facebook.com/TGAgovau/>



TGA Twitter <https://twitter.com/TGAgovau>



TGA YouTube <https://www.youtube.com/channel/UCem9INJbMSOeW1Ry9cNbucw>



TGA topics blog <https://www.tga.gov.au/blogs/tga-topics>



TGA LinkedIn <https://www.linkedin.com/company/therapeutic-goods-administration/>



TGA Instagram <https://www.instagram.com/tgagovau/?hl=en>

SME Assist

↔ tga.gov.au/sme-assist

* sme.assist@tga.gov.au

(1800 020 653

Rebecca Bateson and Brian Chamberlain are currently reading over
your submitted questions.

We'll be back shortly for **Q&A**

We appreciate your participation to complete our live poll.

LIVE POLL

Q&A



Rebecca Bateson
Assistant Director in the Devices Emerging
Technology and Diagnostics Section



Brian Chamberlain
Manager of the Medical Devices
Information Unit (MDIU)



Australian Government

Department of Health
Therapeutic Goods Administration